Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.
Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M, McCallister S. Huhn GD, et al. Among authors: tebas p. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):193-200. doi: 10.1097/QAI.0000000000001193. J Acquir Immune Defic Syndr. 2017. PMID: 27753684 Free PMC article. Clinical Trial.
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; AIDS Clinical Trials Group (ACTG). Tebas P, et al. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):193-200. doi: 10.1097/QAI.0b013e318042e204. J Acquir Immune Defic Syndr. 2007. PMID: 17527093 Free PMC article. Clinical Trial.
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P; Adult Clinical Trials Group 384. Dubé MP, et al. Among authors: tebas p. J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):508-14. doi: 10.1097/QAI.0b013e3181142d26. J Acquir Immune Defic Syndr. 2007. PMID: 17589373 Clinical Trial.
Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.
Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I, Chiu YY, Evans C, Rowell L, Salgo M. Tebas P, et al. J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):342-5. doi: 10.1097/QAI.0b013e31816237f0. J Acquir Immune Defic Syndr. 2008. PMID: 18091608 Clinical Trial.
287 results